TScan Therapeutics, Inc. (TCRX)

NASDAQ: TCRX · IEX Real-Time Price · USD

8.56

-0.09 (-1.04%)

At close: May 3, 2024, 4:00 PM

8.72

+0.16 (1.87%)

After-hours: May 3, 2024, 6:24 PM EDT

TScan Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	138.39	125.06	166.44	35.39	42.36
Short-Term Investments	58.69	0	0	0	0
Cash & Cash Equivalents	197.08	125.06	166.44	35.39	42.36
Cash Growth	57.58%	-24.86%	370.34%	-16.46%	-
Other Current Assets	-2.84	-0.94	-0.78	1.06	0.02
Total Current Assets	194.24	124.13	165.65	36.45	42.38
Property, Plant & Equipment	71.23	69.2	17.26	12.53	6.41
Long-Term Investments	1.65	0.73	0.17	0	0
Other Long-Term Assets	5.03	5.04	5.03	0.76	0.6
Total Long-Term Assets	77.91	74.96	22.45	13.29	7
Total Assets	272.15	199.09	188.11	49.74	49.38
Accounts Payable	2.37	2.91	1.77	2.91	1.01
Deferred Revenue	15.76	3.87	12.91	19.44	0
Current Debt	6.59	3.68	1.65	1.42	0.44
Other Current Liabilities	5.09	6.84	5.02	-6.32	0.94
Total Current Liabilities	29.82	17.31	21.34	17.45	2.4
Long-Term Debt	85.84	82.3	4.39	6.02	4.44
Other Long-Term Liabilities	5.62	0.05	1.59	9.05	0
Total Long-Term Liabilities	91.46	82.35	5.99	15.07	4.44
Total Liabilities	121.28	99.66	27.33	32.52	6.84
Total Debt	92.43	85.98	6.04	7.43	4.89
Debt Growth	7.50%	1322.87%	-18.71%	52.12%	-
Retained Earnings	-247.6	-158.38	-92.16	-43.53	-17.41
Shareholders' Equity	150.87	99.43	160.78	-42.46	-17.14
Net Cash / Debt	104.64	39.08	160.39	27.95	37.47
Net Cash / Debt Growth	167.76%	-75.63%	473.82%	-25.41%	-
Net Cash Per Share	1.60	1.63	13.75	30.51	97.31
Working Capital	164.42	106.82	144.31	19	39.98
Book Value Per Share	2.30	4.13	13.79	-46.35	-44.50

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).